|By Marketwired .||
|May 6, 2014 02:00 AM EDT||
MANCHESTER, UNITED KINGDOM -- (Marketwired) -- 05/06/14 -- Epistem Holdings Plc (LSE: EHP)(AIM: EHP.L), Manchester, UK, the Personalised Medicine and Biotechnology company, announces today the successful presentation and demonstration of the Genedrive® IL28B genotype test at the 49th Annual Meeting of the European Association for the Study of Liver (EASL) held at the ExCeL Arena in London on 10th & 11th April 2014. A single nucleotide polymorphism (SNP) predicts the response to hepatitis C (HCV) treatment with interferon. From buccal swabs provided by conference delegates, Epistem demonstrated successful IL28B genotype results in a rapid test using the Genedrive® device.
Genedrive® is a small, handheld 'Point of Care' molecular diagnostic device which has been developed by Epistem to provide a major advance in next generation diagnostic and genotype testing. Genedrive® provides a rapid (less than an hour), low cost, simple to use platform enabling high sensitivity DNA genotyping analysis. Genedrive® has broad application across a range of areas including bacterial, viral and fungal identification as well as germline and somatic genotype analysis.
The IL28B Genedrive® test represents the completion of the first stage of a HCV panel test to aid in selection of patients who will respond to treatment with pegylated-interferon and/or ribavirin therapy. Epistem is also developing diagnostic and viral load tests to aid patient clinical and therapy management. The IL28b test will be made available as a Research Use Only product over the coming months and will be followed by subsequent CE-IVD regulatory approval. The IL28B test is the first of a panel of HCV tests that Epistem is developing alongside the European Commission's 7th Framework Programme for the development of Point of Care HCV tests.
For further details please contact Epistem at www.epistem.co.uk
Notes for editors
Epistem is a biotechnology company commercialising its expertise in stem cells in the areas of infectious and epithelial disease (oncology, gastrointestinal and dermatological). Epistem develops innovative therapeutics, biomarkers and diagnostics (Genedrive®) alongside contract research services to drug development companies. Epistem operates three divisions, Personalised Medicine (Biomarkers and Diagnostics), Preclinical Research Services and Novel Therapies.
Personalised Medicine (Biomarkers and Diagnostics)
For DNA genotype analysis, Epistem utilizes its proprietary Point of Care platform, Genedrive®. Genedrive® provides a major advance in next generation molecular diagnostic testing by providing a rapid, low cost, simple to use 'Point of Care' device with high sensitivity. Genedrive® has applications across a wide range of areas including bacterial, viral and fungal identification as well as germline and somatic genotype analysis.
The Biomarker and Personalised Medicine Division provides services to drug development companies in gene expression (mRNA/miRNA) or DNA genotype analysis. For RNA analysis, Epistem utilises its proprietary RNA- Amp biomarker platform. RNA-Amp is a highly sensitive cDNA amplification technique for gene expression analysis of tissue biopsies, blood, plucked scalp hair, skin and laser captured microdissected (LCM) samples to measure drug-induced gene expression changes. Epistem's knowledge of epithelial cells and the ability to obtain gene expression information from small starting materials enables the group to be a preferred partner of choice for Pharmaceutical and Biotechnology companies in providing biomarker information to support drug development programmes.
Matthew Walls: Chief Executive Officer
Ben Reed (Pharmacogenomics - Business Development)
Gino Miele (Pharmacogenomics - Operations Director)
+44 (0) 161 606 7258
In his session at @DevOpsSummit at 19th Cloud Expo, Yoseph Reuveni, Director of Software Engineering at Jet.com, will discuss Jet.com's journey into containerizing Microsoft-based technologies like C# and F# into Docker. He will talk about lessons learned and challenges faced, the Mono framework tryout and how they deployed everything into Azure cloud. Yoseph Reuveni is a technology leader with unique experience developing and running high throughput (over 1M tps) distributed systems with extre...
Jul. 28, 2016 10:15 PM EDT Reads: 2,214
"We've discovered that after shows 80% if leads that people get, 80% of the conversations end up on the show floor, meaning people forget about it, people forget who they talk to, people forget that there are actual business opportunities to be had here so we try to help out and keep the conversations going," explained Jeff Mesnik, Founder and President of ContentMX, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 28, 2016 10:15 PM EDT Reads: 1,435
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Jul. 28, 2016 10:15 PM EDT Reads: 1,193
Jul. 28, 2016 10:00 PM EDT Reads: 1,715
Jul. 28, 2016 10:00 PM EDT Reads: 1,440
Jul. 28, 2016 10:00 PM EDT Reads: 2,094
Jul. 28, 2016 09:00 PM EDT Reads: 2,702
Jul. 28, 2016 07:15 PM EDT Reads: 1,229
Jul. 28, 2016 07:15 PM EDT Reads: 369
Jul. 28, 2016 06:45 PM EDT Reads: 1,635
Jul. 28, 2016 06:30 PM EDT Reads: 1,661
Jul. 28, 2016 06:00 PM EDT Reads: 956
Jul. 28, 2016 05:30 PM EDT Reads: 1,865
Jul. 28, 2016 05:30 PM EDT Reads: 2,214
Jul. 28, 2016 05:00 PM EDT Reads: 432